RecruitingPhase 2NCT06989359

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

Sponsor

ADARx Pharmaceuticals, Inc.

Enrollment

45 participants

Start Date

Aug 28, 2025

Study Type

INTERVENTIONAL

Conditions

IgA Nephropathy (IgAN)IgAN C3G IC-MPGN Complement-mediated Kidney Disease

Summary

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ADX-038 Dose Level 1 and a drug called ADX-038 Dose Level 2 for people with c3g, complement-mediated kidney disease, and other related conditions. The study is currently recruiting participants at 25 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGADX-038 Dose Level 2

siRNA duplex oligonucleotide

DRUGADX-038 Dose Level 1

siRNA duplex oligonucleotide

Locations(29)

ADARx Clinical Site

Doral, Florida, United States

ADARx Clinical Site

Miami, Florida, United States

ADARx Clinical Site

Pembroke Pines, Florida, United States

ADARx Clinical Site

Iowa City, Iowa, United States

ADARx Clinical Site

Shreveport, Louisiana, United States

ADARx Clinical Site

Shelby, Michigan, United States

ADARx Clinical Site

Great Neck, New York, United States

ADARx Clinical Site

Columbus, Ohio, United States

ADARx Clinical Site

Dakota Dunes, South Dakota, United States

ADARx Clinical Site

Dallas, Texas, United States

ADARx Clinical Site

Houston, Texas, United States

ADARx Clinical Site

Liverpool, New South Wales, Australia

ADARx Clinical Site

Wollongong, New South Wales, Australia

ADARx Clinical Site

Sydney, Australia

ADARx Clinical Site

Woolloongabba, Australia

ADARx Clinical Site

Hong Kong, Hong Kong

ADARx Clinical Site

Shatin, Hong Kong

ADARx Clinical Site

Wŏnju, Gangwon-do, South Korea

ADARx Clinical Site

Cheonan, South Korea

ADARx Clinical Site

Daegu, South Korea

ADARx Clinical Site

Gyeonggi-do, South Korea

ADARx Clinical Site

Seoul, South Korea

ADARx Clinical Site

Seoul, South Korea

ADARx Clinical Site

Seoul, South Korea

ADARx Clinical Site

Seoul, South Korea

ADARx Clinical Site

Barcelona, Spain

ADARx Clinical Site

Madrid, Spain

ADARx Clinical Site

Seville, Spain

ADARx Clinical Site

Newcastle upon Tyne, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06989359

Related Trials

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)

NCT069262441 location

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(29)

Related Trials

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

Atacicept in Multiple Glomerular Diseases

Chinese Adults With Kidney Disease

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)